PayerTalkCE® Presents: Case Challenge: T1 Diabetes Patient with Diabetic Retinopathy


Expert Faculty Presenters

Dana McCormick, RPh, FAMCP
Senior Director, Pharmacy Advisory Services
Optum Insights
Click here for biography

Adrienne W. Scott, MD
Retina Specialist
Associate Professor of Ophthalmology
Wilmer Eye/John Hopkins
Click here for biography

Target Audience

This activity is designed to meet the educational needs of managed care pharmacy directors, registered nurses, clinical pharmacists, quality directors and medical directors.

Statement of Need/Program Overview

Within the space of just a few years, several new retinal treatments have been approved for diabetic retinopathy (DR), promising increased durability and better patient outcomes. These conditions can significantly impact vision and quality of life for patients. The program will explore the pathophysiology of DR via a case study analysis. During the analysis expert faculty will discuss pharmacologic treatment options and the impact of utilization management programs and SDOH on patients.

Educational Objectives 
After completing this activity, the participant should be better able to:

Accreditation Information

Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Medical Education Resources (MER) and Impact Education, LLC. MER is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team

Physician Continuing Medical Education
Medical Education Resources designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education
Medical Education Resources designates this continuing education activity for 0.5 contact hour (0.05 CEU) of the Accreditation Council for Pharmacy Education.

Universal Activity Number: JA0003680-9999-25-068-H01-P
This activity is certified as Knowledge-based CPE.

Please note: Pharmacists have up to 30 days to complete the evaluation and claim credit for participation so that information can be submitted to CPE Monitor as required.

Continuing Nursing Education
Medical Education Resources designates this enduring material for a maximum of 0.5 ANCC nursing contact hours. Nurses will be awarded contact hours upon successful completion of the activity.

Medical Education Resources is a provider of continuing nursing education by the California Board of Registered Nursing, Provider #CEP 12299, for 0.5 contact hours.

Disclosure of All Financial Relationships
Medical Education Resources ensures balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, MER identifies all relevant financial relationships with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Reported relevant financial relationships are mitigated by MER to ensure that all scientific research referred to, reported, or used in a CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing learners with high-quality CE activities that promote improvements or quality in health care and not the business interest of an ineligible company.

The authors reported the following financial relationships with ineligible companies whose products or services may be mentioned in this activity:

Name of Working Group Members/Planners Reported Financial Relationship

Dana McCormick, RPh, FAMCP

Nothing to disclose.

Adrienne W. Scott, MD

Grants/Research Support - Genentech/Roche
Consulting fees (eg. Ad Boards) - EyePoint, Genentech Roche, Regeneron, Iveric Bio, Astellas
Speakers' Bureaus - Allergan, Abbvie

The content managers reported the following financial relationships with ineligible companies whose products or services may be mentioned in this activity:

Name of Content Managers Reported Financial Relationship

Impact Education, LLC.

No financial relationships to disclose

Planners at Medical Education Resources

No financial relationships to disclose

METHOD OF PARTICIPATION
There are no fees for participating in and receiving credit for this activity. During the accreditation period, participants must 1) read the learning objectives and faculty disclosures, 2) study the educational activity, and 3) complete the evaluation form.

A statement of credit will be issued only upon receipt of a completed activity evaluation form.

DISCLAIMER
The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Medical Education Resources, Impact Education, LLC, and/or Regeneron Pharmaceuticals, Inc. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

FEE INFORMATION
There is no fee for this educational activity.